Vogenx
Business Services · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3920 S Alston Ave, Durham, North Carolin...Phone Number
(919) 659-5677Website
www.vogenx.comRevenue
<$5 MillionIndustry
About Vogenx
Vogenx Org Chart
Is Vogenx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Vogenx had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Vogenx
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Vogenx launches new products
Check if Vogenx has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Vogenx has new funding data
Check out if Vogenx is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Vogenx recently announced quarterly report
Vogenx, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Vogenx
Find 3 more new buyers
Compare Similar Companies to Vogenx
Compare insights from companies similar to Vogenx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vogenx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vogenx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vogenx.
Vogenx Tech Stack
A closer look at the technologies used by Vogenx
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Vogenx
Vogenx is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for metabolic and gastrointestinal diseases, particularly focusing on post bariatric hypoglycemia and gastroparesis. Their lead compound, mizagliflozin, is an oral small molecule drug that inhibits postprandial glucose absorption and reduces insulin secr... Read More